About this Journal Submit a Manuscript Table of Contents
Multiple Sclerosis International
Volume 2012 (2012), Article ID 862169, 6 pages
http://dx.doi.org/10.1155/2012/862169
Review Article

Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?

Department of Neurology, Osaka University Graduate School of Medicine, D4, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

Received 27 October 2011; Revised 28 December 2011; Accepted 4 January 2012

Academic Editor: Jerome de Seze

Copyright © 2012 Makoto Kinoshita and Yuji Nakatsuji. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. V. A. Lennon, D. M. Wingerchuk, T. J. Kryzer et al., “A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis,” The Lancet, vol. 364, no. 9451, pp. 2106–2112, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. V. A. Lennon, T. J. Kryzer, S. J. Pittock, A. S. Verkman, and S. R. Hinson, “IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel,” Journal of Experimental Medicine, vol. 202, no. 4, pp. 473–477, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. L. Bennett, C. Lam, S. R. Kalluri et al., “Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica,” Annals of Neurology, vol. 66, no. 5, pp. 617–629, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. Bradl, T. Misu, T. Takahashi et al., “Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo,” Annals of Neurology, vol. 66, no. 5, pp. 630–643, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. Kinoshita, Y. Nakatsuji, T. Kimura et al., “Neuromyelitis optica: passive transfer to rats by human immunoglobulin,” Biochemical and Biophysical Research Communications, vol. 386, no. 4, pp. 623–627, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. Saadoun, P. Waters, B. A. Bell, A. Vincent, A. S. Verkman, and M. C. Papadopoulos, “Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice,” Brain, vol. 133, no. 2, pp. 349–361, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S. Watanabe, I. Nakashima, T. Misu et al., “Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica,” Multiple Sclerosis, vol. 13, no. 1, pp. 128–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Miyamoto and S. Kusunoki, “Intermittent plasmapheresis prevents recurrence in neuromyelitis optica,” Therapeutic Apheresis and Dialysis, vol. 13, no. 6, pp. 505–508, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. T. Takahashi, K. Fujihara, I. Nakashima et al., “Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre,” Brain, vol. 130, no. 5, pp. 1235–1243, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. Jarius, F. Aboul-Enein, P. Waters et al., “Antibody to aquaporin-4 in the long-term course of neuromyelitis optica,” Brain, vol. 131, no. 11, pp. 3072–3080, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. I. Dujmovic, S. Mader, K. Schanda et al., “Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders,” Journal of Neuroimmunology, vol. 234, no. 1-2, pp. 124–130, 2011. View at Publisher · View at Google Scholar · View at PubMed
  12. T. Misu, K. Fujihara, A. Kakita et al., “Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis,” Brain, vol. 130, no. 5, pp. 1224–1234, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. S. F. Roemer, J. E. Parisi, V. A. Lennon et al., “Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis,” Brain, vol. 130, no. 5, pp. 1194–1205, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. M. Kinoshita, Y. Nakatsuji, M. Moriya et al., “Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum,” NeuroReport, vol. 20, no. 5, pp. 508–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Sabater, A. Giralt, A. Boronat et al., “Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study,” Journal of Neuroimmunology, vol. 215, no. 1-2, pp. 31–35, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. R. Hinson, S. F. Roemer, C. F. Lucchinetti et al., “Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2,” Journal of Experimental Medicine, vol. 205, no. 11, pp. 2473–2481, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. T. Vincent, P. Saikali, R. Cayrol et al., “Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment,” Journal of Immunology, vol. 181, no. 8, pp. 5730–5737, 2008. View at Scopus
  18. C. F. Lucchinetti, R. N. Mandler, D. McGavern et al., “A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica,” Brain, vol. 125, no. 7, pp. 1450–1461, 2002. View at Scopus
  19. S. R. Hinson, S. J. Pittock, C. F. Lucchinetti et al., “Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica,” Neurology, vol. 69, no. 24, pp. 2221–2231, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. M. Kinoshita, Y. Nakatsuji, T. Kimura et al., “Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells,” Biochemical and Biophysical Research Communications, vol. 394, no. 1, pp. 205–210, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J.-I. Kira, “Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders,” Journal of the Neurological Sciences, vol. 311, no. 1-2, pp. 69–77, 2011. View at Publisher · View at Google Scholar · View at PubMed
  22. S. Jarius, F. Paul, D. Franciotta et al., “Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica,” Nature Clinical Practice Neurology, vol. 4, no. 4, pp. 202–214, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. T. Matsushita, N. Isobe, T. Matsuoka et al., “Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese,” Multiple Sclerosis, vol. 15, no. 7, pp. 834–847, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. Nishiyama, T. Ito, T. Misu et al., “A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset,” Neurology, vol. 72, no. 22, pp. 1960–1961, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. B. Diamond, P. T. Huerta, P. Mina-Osorio, C. Kowal, and B. T. Volpe, “Losing your nerves? Maybe it's the antibodies,” Nature Reviews Immunology, vol. 9, no. 6, pp. 449–456, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. T. Miwa and W. C. Song, “Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases,” International Immunopharmacology, vol. 1, no. 3, pp. 445–459, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Rus, C. Cudrici, S. David, and F. Niculescu, “The complement system in central nervous system diseases,” Autoimmunity, vol. 39, no. 5, pp. 395–402, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. Billiau and P. Matthys, “Modes of action of Freund's adjuvants in experimental models of autoimmune diseases,” Journal of Leukocyte Biology, vol. 70, no. 6, pp. 849–860, 2001. View at Scopus
  29. V. Raghavendra, F. Y. Tanga, and J. A. DeLeo, “Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS,” European Journal of Neuroscience, vol. 20, no. 2, pp. 467–473, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. K. Miyamoto, N. Nagaosa, M. Motoyama, K. Kataoka, and S. Kusunoki, “Upregulation of water channel aquaporin-4 in experimental autoimmune encephalomyeritis,” Journal of the Neurological Sciences, vol. 276, no. 1-2, pp. 103–107, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. S. R. Kalluri, V. Rothhammer, O. Staszewski et al., “Functional characterization of aquaporin-4 specific t cells: towards a model for Neuromyelitis optica,” PLoS ONE, vol. 6, no. 1, Article ID e16083, 2011. View at Publisher · View at Google Scholar · View at PubMed
  32. M. Pohl, M.-T. Fischer, S. Mader et al., “Pathogenic T cell responses against aquaporin 4,” Acta Neuropathologica, vol. 122, no. 1, pp. 21–34, 2011. View at Publisher · View at Google Scholar · View at PubMed
  33. N. Matsuya, M. Komori, K. Nomura et al., “Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica,” International Immunology, vol. 23, no. 9, pp. 565–573, 2011. View at Publisher · View at Google Scholar · View at PubMed
  34. H. Ochi, X. M. Wu, M. Osoegawa et al., “Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis,” Journal of Neuroimmunology, vol. 119, no. 2, pp. 297–305, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Li, H. Wang, Y. Long, Z. Lu, and X. Hu, “Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis,” Journal of Neuroimmunology, vol. 234, no. 1-2, pp. 155–160, 2011. View at Publisher · View at Google Scholar · View at PubMed
  36. H. H. Wang, Y. Q. Dai, W. Qiu et al., “Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse,” Journal of Clinical Neuroscience, vol. 18, no. 10, pp. 1313–1317, 2011. View at Publisher · View at Google Scholar · View at PubMed
  37. D. M. Wingerchuk, V. A. Lennon, C. F. Lucchinetti, S. J. Pittock, and B. G. Weinshenker, “The spectrum of neuromyelitis optica,” The Lancet Neurology, vol. 6, no. 9, pp. 805–815, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. J. Goverman, “Autoimmune T cell responses in the central nervous system,” Nature Reviews Immunology, vol. 9, no. 6, pp. 393–407, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. H. S. Domingues, M. Mues, H. Lassmann, H. Wekerle, and G. Krishnamoorthy, “Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis,” PLoS ONE, vol. 5, no. 11, Article ID e15531, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. A. McKeon, V. A. Lennon, T. Lotze et al., “CNS aquaporin-4 autoimmunity in children,” Neurology, vol. 71, no. 2, pp. 93–100, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. T. Matsuoka, T. Matsushita, Y. Kawano et al., “Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese,” Brain, vol. 130, no. 5, pp. 1206–1223, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. S. Jarius and B. Wildemann, “AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance,” Nature Reviews Neurology, vol. 6, no. 7, pp. 383–392, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. W. Kim, J. E. Lee, X. F. Li et al., “Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4,” Multiple Sclerosis. In press.
  44. Y. Wang, W. Luo, and G. Reiser, “Proteinase-activated receptor-1 and -2 induce the release of chemokine GRO/CINC-1 from rat astrocytes via differential activation of JNK isoforms, evoking multiple protective pathways in brain,” Biochemical Journal, vol. 401, no. 1, pp. 65–78, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. C. Jauneau, A. Ischenko, P. Chan, and M. Fontaine, “Complement component anaphylatoxins upregulate chemokine expression by human astrocytes,” FEBS Letters, vol. 537, no. 1–3, pp. 17–22, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Tradtrantip., H. Zhang., S. Saadoun. et al., “Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica,” Annals of Neurology. In press.
  47. J. Ratelade, J. L. Bennett, and A. S. Verkman, “Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema,” PLoS ONE, vol. 6, no. 11, Article ID e27412, 2011. View at Publisher · View at Google Scholar · View at PubMed
  48. S. R. Hinson, A. McKeon, J. P. Fryer, M. Apiwattanakul, V. A. Lennon, and S. J. Pittock, “Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells,” Archives of Neurology, vol. 66, no. 9, pp. 1164–1167, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus